Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.48 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL8218834 | 0.83 | CYP1A2 (0.46) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL16336 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL11884703 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL5184074 | 0.82 | GRM8 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL718336 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1532402 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1899059 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL8746869 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1782280 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL218574 | 0.82 | CYP1A2 (0.62) | TSHRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030214-A1 | USE OF COMPATIBLE SOLUTES | MERCK PATENT GMBH (DE) | 2020-01-30 | — | — | US | claimed |
| WO-2018162368-A1 | USE OF COMPATIBLE SOLUTES | MERCK PATENT GMBH (DE) | 2018-09-13 | — | — | WO | claimed |
| EP-3756642-B1 | METHOD TO INCREASE CELLULAR AVAILABILITY OF CALCIUM IN SKIN CELLS AND MIXTURES | MERCK PATENT GMBH (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-11898955-B2 | Devices, systems, and methods for agrochemical detection and agrochemical compositions | SPOGEN BIOTECH INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-110381917-B | Use of compatible solutes | 默克专利股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3702421-B1 | INK-JET INK COMPOSITION AND INK JET RECORDING METHOD | SEIKO EPSON CORP (JP) | 2023-10-18 | — | — | EP | disclosed |
| EP-3287562-B1 | TEXTILE PRINTING METHOD | SEIKO EPSON CORP (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-11737997-B2 | Method to increase cellular availability of calcium in skin cells and mixtures | MERCK PATENT GMBH (DE) | 2023-08-29 | — | — | US | disclosed |
| EP-3382093-B1 | PRETREATMENT LIQUID, INK SET, AND RECORDING METHOD | SEIKO EPSON CORP (JP) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023141799-A1 | A COMPOSITION AGAINST OSMOTIC STRESS | ELC MANAGEMENT LLC (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4220130-A1 | DEVICES, SYSTEMS, AND METHODS FOR AGROCHEMICAL DETECTION AND AGROCHEMICAL COMPOSITIONS | Spogen Biotech Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20050201955-A1 | Use of compatible solutes for inhibiting the release of ceramides | SUSONITY Commercial GmbH (DE) | 2005-09-15 | — | — | US | disclosed |
| US-20040228894-A1 | Moisture retaining component and sesquiterpene alcohol for improving dry or sensitive skin | KAO CORPORATION (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1136062-B1 | Cosmetic use of compositions comprising sesquiterpene alcohol | KAO CORP (JP) | 2004-06-30 | — | — | EP | disclosed |
| US-20040071691-A1 | Pharmaceutical formulation | BITOP AG. | 2004-04-15 | — | — | US | disclosed |
| US-20040043442-A1 | Use of betaine in functional products having blood pressure lowering effects | FINNFEEDS FINLAND OY (FI) | 2004-03-04 | — | — | US | disclosed |
| EP-1357911-A1 | USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING EFFECTS | Finnfeeds Finland Ltd (FI) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002055069-A1 | USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING EFFECTS | FINNFEEDS FINLAND OY (FI) | 2002-07-18 | — | — | WO | disclosed |
| EP-1136062-A1 | Cosmetic compositions comprising sesquiterpene alcohol | Kao Corporation (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-20010019717-A1 | Cosmetic compositions | KAO CORPORATION (JP) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737997-B2 | Method to increase cellular availability of calcium in skin cells and mixtures | CA2, CHERP, SLC8B1 | TSHR 3769/4885CYP1A2 4881/4885GRM8 2847/4885 |
| US-20050201955-A1 | Use of compatible solutes for inhibiting the release of ceramides | CERT1, UGCG, CERS2 | TSHR 4571/4885CYP1A2 4709/4885GRM8 4809/4885 |
| US-20200030214-A1 | USE OF COMPATIBLE SOLUTES | SLC9A5, SLC9A1, SLC9A3 | TSHR 4831/4885CYP1A2 4075/4885GRM8 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.